advertisement
Wang TH 10
Showing records 1 to 10 | Display all abstracts from Wang TH117550 Impact of atropine use for myopia control on intraocular pressure in children: A comprehensive review including postpupil dilation intraocular pressure changes
Chen PJ
Taiwan journal of ophthalmology 2024; 14: 179-189
117535 Omidenepag Isopropyl 0.002% versus Latanoprost 0.005% in Open-Angle Glaucoma/Ocular Hypertension: The Randomized Phase III PEONY Trial
Wang TH; Aung T
Clinical Ophthalmology 2024; 18: 2093-2106
117550 Impact of atropine use for myopia control on intraocular pressure in children: A comprehensive review including postpupil dilation intraocular pressure changes
Hsia Y
Taiwan journal of ophthalmology 2024; 14: 179-189
117535 Omidenepag Isopropyl 0.002% versus Latanoprost 0.005% in Open-Angle Glaucoma/Ocular Hypertension: The Randomized Phase III PEONY Trial
Lu DW
Clinical Ophthalmology 2024; 18: 2093-2106
117550 Impact of atropine use for myopia control on intraocular pressure in children: A comprehensive review including postpupil dilation intraocular pressure changes
Tsai TH; Su CC
Taiwan journal of ophthalmology 2024; 14: 179-189
117535 Omidenepag Isopropyl 0.002% versus Latanoprost 0.005% in Open-Angle Glaucoma/Ocular Hypertension: The Randomized Phase III PEONY Trial
George R
Clinical Ophthalmology 2024; 18: 2093-2106
117550 Impact of atropine use for myopia control on intraocular pressure in children: A comprehensive review including postpupil dilation intraocular pressure changes
Huang JY
Taiwan journal of ophthalmology 2024; 14: 179-189
117535 Omidenepag Isopropyl 0.002% versus Latanoprost 0.005% in Open-Angle Glaucoma/Ocular Hypertension: The Randomized Phase III PEONY Trial
Senthil S
Clinical Ophthalmology 2024; 18: 2093-2106
117550 Impact of atropine use for myopia control on intraocular pressure in children: A comprehensive review including postpupil dilation intraocular pressure changes
Wang TH
Taiwan journal of ophthalmology 2024; 14: 179-189
117535 Omidenepag Isopropyl 0.002% versus Latanoprost 0.005% in Open-Angle Glaucoma/Ocular Hypertension: The Randomized Phase III PEONY Trial
Lu F; Odani-Kawabata N; Park KH
Clinical Ophthalmology 2024; 18: 2093-2106
